← Leaderboards
Raymond Louis Benza
University Of Alabama At Birmingham
$8,437,286
Attributed
$8,437,286
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,437,286 · 8
By mechanism
R01$6,400,159 · 3
R33$671,968 · 1
R21$400,575 · 1
K08$340,929 · 1
R61$335,984 · 1
N01$287,671 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- David M Pollock$22,398,356
- Malgorzata Kasztan$1,628,875
- Michael B Fallon$7,992,553
- Carmen De Miguel$763,135
- Patrick Axel Molina$124,150
Others in their field
Top investigators on “Pulmonary Arterial Hypertension”
- Marlene Rabinovitch · Stanford University$37,720,523
- Steven M Kawut · Columbia University Health Sciences$25,762,724
- Jason X.-J. Yuan · University Of California, San Diego$23,310,307
- Mark Thomas Gladwin · Clinical Center$17,771,315
- William C Nichols · Children'S Hospital Med Ctr (Cincinnati)$16,040,000
- Vasan S. Ramachandran · Boston University Medical Campus$14,020,252
Research focus
Pulmonary Arterial HypertensionPulmonary HypertensionCohortResourcesTrainingFutureValidationClinical TrialsGenerationsResponsePulmonary VesselsProspectiveEffective TherapyMonitorBiomedical EngineeringCost EffectivenessDisease ProgressionConsensusComputer ScienceCostDatabasesClinical Trials DesignCommunitiesClinical Predictors
Grant awards (21)
PHORA-Pulmonary Hypertension Outcome Risk Assessment$543,703
R01 · FY2025 · HL · contact PI
The Development of a Biatrial Catheter for a Cardiopulmonary Support System in Pulmonary Arterial Hypertension$335,984
R33 · FY2025 · HL · contact PI
PHORA-Pulmonary Hypertension Outcome Risk Assessment$607,038
R01 · FY2024 · HL · contact PI
The Development of a Biatrial Catheter for a Cardiopulmonary Support System in Pulmonary Arterial Hypertension$335,984
R33 · FY2024 · HL · contact PI
PHORA-Pulmonary Hypertension Outcome Risk Assessment$661,549
R01 · FY2023 · HL · contact PI
The Development of a Biatrial Catheter for a Cardiopulmonary Support System in Pulmonary Arterial Hypertension$335,984
R61 · FY2023 · HL · contact PI
PHORA-Pulmonary Hypertension Outcome Risk Assessment$20,001
R01 · FY2023 · HL · contact PI
PHORA: A Clinical Decision Support Tool for Patients with Pulmonary Arterial Hypertension$656,378
R01 · FY2020 · HL · contact PI
PHORA: A Clinical Decision Support Tool for Patients with Pulmonary Arterial Hypertension$656,406
R01 · FY2019 · HL · contact PI
PHORA: A Clinical Decision Support Tool for Patients with Pulmonary Arterial Hypertension$694,555
R01 · FY2018 · HL · contact PI
PHORA: A Clinical Decision Support Tool for Patients with Pulmonary Arterial Hypertension$749,226
R01 · FY2017 · HL · contact PI
IGF::OT::IGF Vascular Interventions/Innovations and Therapeutic Advances (VITA): A Study to Explore the Feasibility of using Combined Modalities to Test the Safety of CaridMEMS Device in PAH Patients$287,671
N01 · FY2014 · HL · contact PI
Salivary Gland-Based Gene Therapy for Pulmonary Arterial Hypertension$180,075
R21 · FY2014 · HL · contact PI
Salivary Gland-Based Gene Therapy for Pulmonary Arterial Hypertension$220,500
R21 · FY2013 · HL · contact PI
Pharmacogenomics in Pulmonary Arterial Hypertension$451,702
R01 · FY2008 · HL · contact PI
Pharmacogenomics in Pulmonary Arterial Hypertension$445,556
R01 · FY2007 · HL · contact PI
Pharmacogenomics in Pulmonary Arterial Hypertension$450,628
R01 · FY2006 · HL · contact PI
Pharmacogenomics in Pulmonary Arterial Hypertension$463,417
R01 · FY2005 · HL
GENETIC DETERMINATION OF ALLOGRAFT VASCULOPATHY$113,643
K08 · FY2002 · HL
GENETIC DETERMINATION OF ALLOGRAFT VASCULOPATHY$113,643
K08 · FY2001 · HL
GENETIC DETERMINATION OF ALLOGRAFT VASCULOPATHY$113,643
K08 · FY2000 · HL